AXIOS November 26, 2024
Ivana Saric, Tina Reed

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover anti-obesity drugs.

Why it matters: The rule would expand access to medications known as GLP-1 agonists for millions of Americans struggling with obesity, who are at higher risk of diabetes, stroke and cardiovascular disease, according to a White House fact sheet.

  • The proposal could set up a conflict between pharmaceutical companies and Robert F. Kennedy Jr., President-elect Trump’s nominee for secretary of the Health and Human Services Department, who is an Ozempic critic.

Driving the news: Under current law, Medicare is barred from covering drugs for weight loss. That also makes it optional for state Medicaid plans, officials said.

  • The new rule proposes a “reinterpretation”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare, Patient / Consumer, Pharma / Biotech, Provider
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more

Share This Article